Company Overview of Formula Pharmaceuticals, Inc.
Formula Pharmaceuticals, Inc., a biopharmaceutical company, develops Chimeric Antigen Receptor (“CAR”) immunotherapies to address critical unmet medical needs in cancer. The company primarily focuses on the development of allogeneic CIK-CAR.CD19 for B cell malignancies, followed by the development of allogeneic CIK-CAR.CD33 for myeloid leukemias; a CIK-CAR.PSMA program and other targets for solid tumors; and targets for multiple myeloma. Formula Pharmaceuticals, Inc. was founded in 2009 and is based in Berwyn, Pennsylvania.
1055 Westlakes Drive
Berwyn, PA 19312
Founded in 2009
Key Executives for Formula Pharmaceuticals, Inc.
Founder, Chairman, Chief Executive Officer and President
Acting Chief Financial Officer
Vice President of Operations
Executive Vice President of Strategic Affairs, General Counsel and Secretary
Compensation as of Fiscal Year 2016.
Formula Pharmaceuticals, Inc. Key Developments
Formula Pharmaceuticals Appoints Malcolm K. Brenner, MD, PhD to its Scientific Advisory Board
May 5 16
Formula Pharmaceuticals, Inc. announced the appointment of Dr. Malcolm K. Brenner, Founding Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, as a member of its Scientific Advisory Board (SAB). The SAB serves as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer (C.I.K.) cells targeting cancer and autoimmune disease. Malcolm Brenner is a professor in the departments of Pediatrics and Medicine, Section of Hematology-Oncology at Baylor College of Medicine. He is also Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, The Methodist Hospital and Texas Children’s Hospital. Dr. Brenner is an associate editor of Blood and of Molecular Therapy, and he is the principal investigator or co-investigator on National Institutes of Health grants.
Formula Pharmaceuticals, Inc. and Rockland Immunochemicals, Inc. Enter into a Collaboration to Develop C.I.K. Car Immunotherapy Pipeline for the Treatment of Cancer
Feb 22 16
Formula Pharmaceuticals, Inc. and Rockland Immunochemicals, Inc. announced the establishment of a collaboration for the preclinical development of Formula’s Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) cancer immunotherapies at Rockland’s R&D facility. Under the collaboration, Rockland will provide and manage Formula’s specially hired preclinical research team. Further, Rockland will provide the classified research facilities for Formula’s preclinical development needs in its newly established, scalable 60,000 sq ft R&D facility. Formula’s immunotherapy product pipeline is built upon a proprietary, non-viral, allogeneic C.I.K. CAR™ technology platform, which seeks to overcome practical and therapeutic limitations related to existing CAR-T approaches that include viral transfection, autologous blood and T cells. Formula’s C.I.K. CAR™ technology leverages T cell and Natural Killer cell functionality within one effector cell population sourced from healthy donor peripheral or cord blood, which the Company is developing as an off-the-shelf CAR immunotherapy for hematologic and solid tumor indications.
Formula Pharmaceuticals, Inc. Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016
Jan 7 16
Formula Pharmaceuticals, Inc. Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016 . Venue: Marine's Memorial Club & Hotel, 609 Sutter St, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|